Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported compensation-related stock activity tied to restricted stock units (RSUs). On March 13, 2026, he converted vested RSUs into 72,108 shares of Class A common stock.
To satisfy tax withholding obligations on these vestings, the company withheld a total of 237,756 shares of Class A common stock at $24.77 per share, rather than selling shares on the open market. After all exercises and tax withholdings, Chi directly holds 504,571 shares of Class A common stock.
The RSUs are subject to service-based vesting over four-year periods, with quarterly vesting dates beginning on various schedules between June 15, 2022 and June 15, 2025.
Hims & Hers Health, Inc. director Christiane Pendarvis exercised previously granted restricted stock units, converting 15,211 RSUs into the same number of Class A common shares at a price of $0.00 per share, reflecting equity compensation rather than an open-market purchase.
The RSUs vest over three years, with one-third vesting on March 15, 2024, one-third on March 15, 2025, and one-third on March 15, 2026. Following this conversion, Pendarvis directly holds 51,774 Class A shares, and the filing shows no sales or tax-withholding disposals, indicating a straightforward exercise-and-hold event.
Hims & Hers Health, Inc. director and Chief Medical Officer Carroll Patrick Harrison reported the vesting and settlement of restricted stock units into Class A Common Stock. On March 13, 2026, RSU awards for 8,149, 4,840 and 3,533 units converted into a total of 16,522 Class A shares at a conversion price of $0.00.
To satisfy tax withholding obligations related to this RSU vesting, 4,022 Class A shares were withheld by the issuer at $24.77 per share, a non‑market, tax-withholding disposition rather than an open-market sale. Following these transactions, Harrison holds 182,440 Class A Common shares directly.
Hims & Hers Health, Inc. director and Chief Policy Officer Deborah M. Autor exercised and settled 32,919 Restricted Stock Units (RSUs) into the same number of Class A Common shares on March 13, 2026. Of these, 11,312 shares of Class A Common Stock, valued at $24.77 per share, were withheld by the company to cover tax withholding obligations related to the RSU vesting. Following these transactions, she directly owned 27,782 shares of Class A Common Stock, and 493,792 RSUs remained outstanding, each representing a contingent right to receive one share. The remaining RSUs are subject to service-based vesting in substantially equal quarterly installments on March 15, June 15, September 15 and December 15 over a four-year period, beginning on March 15, 2026.
Hims & Hers Health, Inc. principal accounting officer Irene Becklund exercised and settled multiple restricted stock unit (RSU) awards into 17,987 shares of Class A Common Stock on March 13, 2026. Each RSU converts into one share of Class A Common Stock.
To cover tax withholding obligations tied to these RSU vestings, 5,832 shares were withheld by the company at a price of $24.77 per share, a non-market, tax-related disposition rather than an open-market sale. Following these transactions, Becklund directly holds 14,281 shares of Class A Common Stock. The RSUs vest based on continued service over four-year schedules with quarterly vesting dates.
Hims & Hers Health, Inc. Chief Executive Officer Andrew Dudum reported the vesting and settlement of restricted stock units on March 13, 2026. The RSU conversions resulted in the acquisition of 164,369 shares of Class A common stock. To cover tax withholding obligations related to these RSUs and performance RSUs that vested on February 23, 2026, the issuer withheld a total of 526,486 shares of Class A common stock at $24.77 per share, which is recorded as a tax-withholding disposition rather than an open-market sale. Following these transactions, Dudum held 1,310,617 Class A shares directly, and also reported additional indirect holdings through several family trusts, including positions such as 3,004,071 shares held by the Trustee of the Dudum Family 2021 Trust and 2,214,769 shares held by the Trustee of the Dudum Family Heritage Trust UAD 8-10-2021.
Hims & Hers Health, Inc. Chief Legal Officer Soleil Boughton reported routine equity compensation activity involving restricted stock units (RSUs) on March 13, 2026. Multiple RSU awards covering a total of 41,421 units were exercised or converted, each RSU representing one share of Class A common stock.
To cover tax withholding obligations tied to the vesting and settlement of these RSUs, the issuer withheld 168,750 shares of Class A common stock at a price of $24.77 per share, classified as tax-withholding dispositions rather than market sales. Following these transactions, Boughton directly holds 313,643 shares of Class A common stock.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported equity compensation activity involving restricted stock units and Class A Common Stock. On March 13, 2026, RSUs converted into 105,200 shares of Class A Common Stock as they vested under multi‑year service-based schedules.
To cover tax withholding obligations tied to vested performance RSUs and other RSUs, the issuer withheld a total of 283,990 shares of Class A Common Stock at $24.77 per share, characterized as tax-withholding dispositions rather than market sales. Following these transactions, Okupe directly held 323,517 Class A Common shares and indirectly held 7,853 shares through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
HIMS reported a proposed sale of Class A shares under Rule 144. The filing lists 03/15/2026 vesting of 4,812 Class A shares as restricted stock and identifies a planned sale notification. The filing also records a 02/27/2026 sale by Soleil Boughton of 4,651 Class A shares for $70,741.71.
HIMS reported a Form 144 notifying a proposed sale of Class A common shares. The filing lists $136,511.01 tied to 5,529 Class A shares through Fidelity Brokerage Services with a filing date of 03/17/2026 on the NYSE.
The record also shows a prior disposition by Irene Becklund of 8,411 Class A shares on 12/17/2025 for $308,767.81. The securities listed include restricted shares that vested on 03/15/2026 and are labeled as compensation.